Literature DB >> 21317591

A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.

Laura W Cheever1, Thomas F Kresina, Adan Cajina, Robert Lubran.   

Abstract

A Health Resources and Services Administration-Substance Abuse and Mental Health Services Administration collaboration was established to improve health outcomes for opiate-dependent HIV-infected patients through promotion of integrated models of HIV primary care and substance abuse treatment. The collaboration comprised 10 demonstration sites coordinated by a technical assistance/evaluation center that worked to refine planned interventions, address state-of-the-art treatment and policy issues relating to the use of buprenorphine opioid abuse treatment in HIV primary care settings, conduct local and multisite evaluations, and disseminate program findings. This article describes the goals and objectives of the collaborative as well as the interagency interactions and steps taken to establish the collaborative.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317591     DOI: 10.1097/QAI.0b013e318209740f

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  19 in total

1.  Do HIV-positive women receive depression treatment that meets best practice guidelines?

Authors:  Judith A Cook; Jane K Burke-Miller; Dennis D Grey; Jennifer Cocohoba; Chenlong Liu; Rebecca M Schwartz; Elizabeth T Golub; Kathryn Anastos; Pamela J Steigman; Mardge H Cohen
Journal:  AIDS Behav       Date:  2014-06

2.  Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?

Authors:  Lynn E Taylor; Michaela A Maynard; Peter D Friedmann; Cynthia J Macleod; Josiah D Rich; Timothy P Flanigan; Diana L Sylvestre
Journal:  J Addict Med       Date:  2012-09       Impact factor: 3.702

3.  Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.

Authors:  P Todd Korthuis; Mary Jo Tozzi; Vijay Nandi; David A Fiellin; Linda Weiss; James E Egan; Michael Botsko; Angela Acosta; Marc N Gourevitch; David Hersh; Jeffrey Hsu; Joshua Boverman; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

4.  HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Authors:  Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; Adan Cajina; Michael Botsko; Vijay Nandi; Marc N Gourevitch; Ruth Finkelstein
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

5.  The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.

Authors:  Bruce R Schackman; Jared A Leff; Michael Botsko; David A Fiellin; Fredrick L Altice; P Todd Korthuis; Nancy Sohler; Linda Weiss; James E Egan; Julie Netherland; Jonathan Gass; Ruth Finkelstein
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

6.  Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.

Authors:  P Todd Korthuis; David A Fiellin; Rongwei Fu; Paula J Lum; Frederick L Altice; Nancy Sohler; Mary J Tozzi; Steven M Asch; Michael Botsko; Margaret Fishl; Timothy P Flanigan; Joshua Boverman; Dennis McCarty
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

Review 7.  Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention.

Authors:  Steffanie A Strathdee; Steven Shoptaw; Typhanye Penniman Dyer; Vu Minh Quan; Apinun Aramrattana
Journal:  Curr Opin HIV AIDS       Date:  2012-07       Impact factor: 4.283

8.  Integrating substance abuse treatment into HIV care: missed opportunities in the AIDS Drug Assistance Program.

Authors:  Erika G Martin; Karen H Wang
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

9.  Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment.

Authors:  Brandon Aden; Allison Dunning; Bohdan Nosyk; Eve Wittenberg; Jeremy W Bray; Bruce R Schackman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

10.  Confronting the emerging epidemic of HCV infection among young injection drug users.

Authors:  Ronald Valdiserri; Jag Khalsa; Corinna Dan; Scott Holmberg; Jon Zibbell; Deborah Holtzman; Robert Lubran; Wilson Compton
Journal:  Am J Public Health       Date:  2014-03-13       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.